Q4 2024 Elite Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Elite Pharmaceuticals Inc (ELTP) reported a significant increase in total revenues, reaching $56.6 million, a 65% increase from the previous year.
- The company achieved a 192% increase in operating income, rising from $3.7 million to $10.8 million.
- Successful commercial launch of the Elite label product line, transforming the business model and increasing profit margins.
- Approval of methotrexate and acquisition of three approved ANDAs, which are expected to contribute to future revenues.
- Strong balance sheet with working capital doubling from $14 million to $28 million and net equity increasing from $29 million to $58 million.
- Despite the revenue growth, Elite Pharmaceuticals Inc (ELTP) experienced an operating cash burn of $3.3 million, compared to a positive cash flow of $3.3 million the previous year.
- The company will not qualify as an accelerated filer due to not meeting certain revenue criteria.
- The transition to in-house marketing and distribution required a large investment in working capital and infrastructure, impacting cash flow.
- Stock-based liabilities and derivative expenses, which fluctuate with stock price, continue to affect financial statements.
- The company has a high number of shares outstanding, which has been a point of concern among shareholders.
Good morning, ladies and gentlemen, and welcome to the Elite Pharmaceuticals conference call. At this time, all lines have been placed on a listen-only mode. Before management begins speaking, the conference has the following statement, Elite would like to remind the listeners that remarks made during this call may contain forward-looking statements that involve risks and uncertainties that are subject to change at any time, including, but not limited to statements about beliefs and expectations regarding forward operating results.
Forward-looking statements are made pursuant to the Safe Harbor provisions of the federal securities laws and represent management's current expectations. Actual results may differ materially. Elite disclaims any obligation to update or revise its forward-looking statements, except as required by law. More complete information regarding forward-looking statements, risks and uncertainties can be found in the reports Elite files with the SEC, which is available on Elite's website at elitepharma.com under the Investor Relations section. Elite encourages you to review these
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
